Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Share-based Compensation (2016 - 2025)

Biomerica's Share-based Compensation history spans 15 years, with the latest figure at $12000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 92.26% year-over-year to $12000.0; the TTM value through Nov 2025 reached $373000.0, down 51.93%, while the annual FY2025 figure was $460000.0, 45.04% down from the prior year.
  • Share-based Compensation for Q4 2025 was $12000.0 at Biomerica, down from $133000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $522180.0 in Q1 2021 and bottomed at $12000.0 in Q4 2025.
  • The 5-year median for Share-based Compensation is $252316.0 (2022), against an average of $237023.4.
  • The largest annual shift saw Share-based Compensation skyrocketed 230.62% in 2021 before it tumbled 92.26% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $314378.0 in 2021, then grew by 1.15% to $318000.0 in 2022, then crashed by 61.64% to $122000.0 in 2023, then increased by 27.05% to $155000.0 in 2024, then crashed by 92.26% to $12000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Share-based Compensation are $12000.0 (Q4 2025), $133000.0 (Q3 2025), and $137000.0 (Q2 2025).